Mr. Huff has led Reata Pharmaceuticals in its development and trials of bardoxolone methyl and other drugs. Mr. Huff was previously the Chief Executive Officer of Ergo Science Corporation, a biopharmaceutical company based in Boston, Massachusetts, that developed neurotransmitter-modulating drugs for the treatment of type 2 diabetes and obesity. Mr. Huff joined Ergo as its first business executive and, under his leadership, Ergo progressed from seed capital to initial public offering in 39 months. Prior to his work with Ergo, Mr. Huff was a senior partner at Dallas law firm, Johnson & Gibbs. Mr. Huff received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University.

Mr. Bass is a Co-founder and Principal of Ojai Goliad, LLC. Mr. Bass was previously an executive director of an Asian regional investment bank based in Hong Kong. Prior to that he was an attorney over a 9 year period with Gibson, Dunn & Crutcher LLP in both California and Hong Kong and served as a managing partner of the firm's Hong Kong office in the mid 1990s. Mr. Bass graduated with a B.A. degree from Yale University and obtained his J.D. degree from Stanford University. 

Mr. McGaughy is a partner in CPMG, Inc. Prior to joining CPMG's predecessor, Cardinal Investment Company in 1997, Mr. McGaughy worked in mergers and acquisitions at Simmons & Company International. Mr. McGaughy currently serves on the boards of several private companies, including Reata Pharmaceuticals. He received his B.A. from The University of Texas (summa cum laude and member of Phi Beta Kappa) and his M.B.A. from Harvard Business School.

Mr. Nielsen is a Partner with Novo Ventures, a life science investment organization associated with Novo Nordisk. In this capacity, he is currently or has in the past been on board of directors of Panacos Pharmaceuticals, Cell Biosciences, NeoMend, Mediquest, CardioOptics, Inc. and Protein Forest. Prior to joining the venture organization, Mr. Nielsen held various management positions within Novo Nordisk.  He received his MSc from the Technical University of Denmark and his Masters in Management of Technology from the Center for Technology, Economics, and Management. 

Mr. Rose founded Cardinal Investment Company, Inc. in 1973, and is the firm's President.  Mr. Rose serves on the boards of several private companies, and is on the board of Drew Industries, Inc. (NYSE:  DW).  Mr. Rose is the former Co-managing Partner of the Texas Rangers. He received his B.S. from The University of Texas and his M.B.A. from Harvard Business School.

Dr. Stone is the Vice President for Technology Development at UT Southwestern. In, he is also a professor of internal medicine, physiology and biochemistry and holder of the NCH Corporation Chair in Molecular Transport. Dr. Stone received his undergraduate education in the Plan II Program at The University of Texas at Austin. He attended medical school at UT Southwestern and received his housestaff training in internal medicine at Columbia Presbyterian Medical Center in New York City. Subsequently, he completed clinical and research fellowship training in Nephrology at UT Southwestern and Cornell University in Ithaca, NY. Dr. Stone has been the recipient of a Searle Scholarship, named an Established Investigator of the American Heart Association.

Ms. Wysenski is currently the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals. Prior to joining Vertex, Ms. Wysenski held the position of Chief Operating Officer at Endo Pharmaceuticals, where she led sales, marketing, commercial operations, supply chain management, human resources and various business development initiatives. Prior to her role at Endo, Ms. Wysenski was a co-founder of EMD Pharmaceuticals, Inc., the North American subsidiary of Merck KGaA, where she held various leadership positions, including the role of President and CEO from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998, Ms. Wysenski held several sales-focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc.